Executive Summary

Valued at USD 668.5 Million in 2025, the Peptide Synthesis Market is forecast to reach USD 1,339.8 Million by 2035, expanding at a CAGR of 7.20% (2025-2035).

Growth centers on therapeutic peptides such as insulin and GLP-1 receptor agonists, cleared for the US market through the FDA’s BLA and NDA pathways and, in the European Union, through the EMA’s centralised procedure; both routes pull volume through Fmoc and Boc amino acid, resin, and coupling-reagent supply chains. CMS reimbursement coding under CPT and HCPCS has widened patient access to GLP-1 receptor agonists, reinforcing the manufacturing demand that follows approved indications, while HTA bodies across Europe weigh biosimilar peptide entrants against originator pricing. The European Union’s REACH restriction on dimethylformamide is pushing sponsors toward enzymatic and cell-free synthesis routes, reshaping reagent selection across the region. Peptide CDMOs operating under ICH GCP and 21 CFR Part 11 data-integrity controls anchor manufacturing quality, and the Biosecure Act is accelerating the onshoring of peptide API capacity away from Chinese suppliers.

North America held 48.59% of the market in 2025, with Europe at 21.44% and Asia Pacific at 20.16%, the latter still anchored by India’s CDSCO-regulated generic peptide API base. Reagents & Consumables led the Product axis and Therapeutics led the Application axis, anchored by insulin and GLP-1 receptor agonist manufacturing.

Solvent-intensive solid-phase chemistry and the cost of substituting reagents to meet the REACH restriction remain the principal constraint on margin. The supplier base is moderately consolidated, with capacity concentrated among established reagent, resin and CDMO manufacturers.

Key Takeaways

• The market stood at USD 668.50 Million in 2025 and is forecast to reach USD 1,339.83 Million by 2035, a CAGR of 7.2%.
• Reagents & Consumables is the largest product category.
• On application, the leading category is Therapeutics.
• North America accounted for 48.6% of the market in 2025.
• 10 suppliers are profiled, in a moderately-consolidated market.

Market Definition and Scope

The Peptide Synthesis Market covers the equipment, reagents and consumables, and services used to assemble, purify and stabilize peptide chains, spanning automated synthesizers, Fmoc and Boc protected amino acids, resins, coupling reagents, and custom synthesis and CDMO services. End use spans therapeutic peptides such as insulin and GLP-1 receptor agonists and diagnostic peptides used in immunoassays and imaging agents.

Excluded are finished peptide drug formulations and commercial dosage manufacturing, which fall under pharmaceutical manufacturing, and non-peptide small-molecule active pharmaceutical ingredient synthesis.

Growth Drivers and Restraints

GLP-1 receptor agonist and insulin demand is pulling reagent and CDMO volume

Expanding use of GLP-1 receptor agonists and insulin in metabolic-disorder treatment, consistent with the diabetes and obesity prevalence trends the CDC tracks, is pulling volume through Fmoc and Boc protected amino acid, Wang and Rink Amide resin, and coupling-reagent supply chains. Sponsors are routing scale-up work to custom peptide synthesis and CDMO services rather than expanding in-house capacity, concentrating the effect in the Reagents & Consumables and Services segments. The Biosecure Act is reinforcing this shift, pushing US sponsors to qualify domestic or allied CDMO capacity ahead of restrictions on named Chinese biomanufacturers. Much of the resulting pull is concentrated in North America, which held 48.59% of the market in 2025, anchored by peptide candidates cleared under the FDA’s NDA and BLA pathways.

EU REACH’s DMF restriction is redirecting reagent chemistry toward enzymatic routes

The European Union’s REACH restriction on dimethylformamide is pushing sponsors toward enzymatic and cell-free synthesis routes, cutting solvent waste by up to 95% relative to conventional solid-phase cleavage and deprotection steps. A process change of this scale typically triggers a variation filing under the EMA centralised procedure before a reformulated peptide API can stay on market, adding lead time that favors CDMOs with established regulatory affairs teams. ISO 14001 certification, increasingly required as a contract prerequisite by sponsors and CDMOs, is favoring reagent and equipment vendors with established green-chemistry credentials, concentrating outsourcing awards in Europe among certified suppliers.

Diagnostic peptide demand from immunoassay and imaging-agent developers is widening the application base

Diagnostic peptides formulated as antigens and biomarkers for immunoassays, radioimmunoassays and diagnostic imaging agents are widening demand beyond therapeutics, requiring analytical instruments such as HPLC systems and mass spectrometers for lot release. Kits built on these peptide antigens fall under the EU’s IVDR, and platforms marketed in the United States typically clear FDA 510(k) or PMA review before adoption; both lengthen validation timelines but lock in vendor relationships once cleared. Coverage follows a similar two-track pattern: US laboratories bill peptide-based immunoassays under CPT and HCPCS codes, while payer uptake in Europe increasingly turns on an HTA verdict rather than regulatory approval alone. This pulls Equipment segment purchases toward purification and isolation systems and lyophilizers, and lifts contract volume for analytical and testing services run to ICH GCP standards. Diagnosis remains the smaller of the two application segments but broadens the addressable base beyond drug development.

Solvent-intensive solid-phase chemistry keeps the cost base high

Solid-phase synthesis consumes large volumes of solvent during cleavage and deprotection, and the EU REACH restriction on dimethylformamide adds a compliance cost to substituting toward enzymatic or cell-free routes. Electronic batch records generated across that switch must still satisfy 21 CFR Part 11, layering a data-integrity cost on top of the chemistry change itself. Smaller reagent and CDMO suppliers without ISO 14001 certification face exclusion from tenders that treat the standard as a prerequisite, and suppliers operating outside CDSCO-aligned quality systems draw added scrutiny when exporting into regulated markets. Capacity concentrates among larger, already-consolidated manufacturers as a result.

Batch-to-batch purity variability slows adoption among smaller sponsors

Long peptide sequences assembled on Merrifield or Wang resin are prone to deletion and truncation impurities that require additional runs through Purification & Isolation Systems and Analytical & Testing Services before a batch clears the release specification set under an FDA or EMA marketing authorization. Smaller biotech sponsors lacking in-house purification capacity absorb this cost directly, extending timelines for custom peptide synthesis orders. This weighs most on the Custom Peptide Synthesis Services sub-segment, where client specifications vary batch to batch.

Market Trends

Custom synthesis volume is shifting to CDMOs as solid-phase, liquid-phase and hybrid methods mature

Sponsors are routing more custom peptide synthesis work to CDMOs and CROs than they build in-house, a shift tied to advances in solid-phase, liquid-phase and hybrid synthesis techniques that lower the cost of assembling longer and more complex sequences. The Biosecure Act is reinforcing this move: sponsors filing a BLA or NDA with the FDA are qualifying contract manufacturing capacity outside China, and CDMOs are expanding 21 CFR Part 11-compliant electronic batch record systems to support that qualification work. This favors the Services segment, particularly Contract Manufacturing and Custom Peptide Synthesis Services, and moves capital spending on synthesizers and purification systems from sponsor sites to contract manufacturers through 2035.

Automated and microwave-assisted synthesizers are displacing manual platforms in equipment purchases

Buyers are replacing manual and semi-automated synthesizers with automated and microwave-assisted platforms, which cut cycle time on solid-phase assembly of longer therapeutic sequences such as GLP-1 receptor agonists manufactured under ICH GCP-aligned process controls for clinical supply. CMS reimbursement codes and CPT/HCPCS coverage for GLP-1 therapies are sustaining order volume for sponsors filing through the FDA and, in the EU, through the EMA centralised procedure, which in turn pulls capital toward Purification & Isolation Systems and Analytical Instruments, including HPLC systems and mass spectrometers, needed to verify purity at higher throughput. It reallocates Equipment segment spending toward the newer instrument classes through 2035.

REACH-compliant, green-chemistry reagents are gaining share in European procurement

The European Union’s REACH restriction on dimethylformamide is prompting reagent suppliers to reformulate cleavage and deprotection chemistries around enzymatic and cell-free routes, cutting solvent waste by up to 95% against conventional solid-phase processing. ISO 14001 certification is becoming a standing requirement in CDMO tender documents alongside the quality data expected under HTA-linked reimbursement review, and suppliers without it are being screened out before pricing. Reagents & Consumables vendors serving Europe are adjusting formulations to remain eligible for contract awards through 2035, while API capacity registered with India’s CDSCO continues to anchor sourcing options outside the region.

Segment Analysis

Product

• Equipment – Instruments such as automated synthesizers, purification systems, and lyophilizers used to assemble, purify, and stabilize peptide chains in laboratories and manufacturing plants
• Peptide Synthesizers

• Automated Synthesizers
• Manual/Semi-automated Synthesizers
• Microwave-assisted Synthesizers

• Purification & Isolation Systems
• Lyophilizers
• Analytical Instruments

• HPLC Systems
• Mass Spectrometers
• Reagents & Consumables (largest) – Amino acids, resins, coupling agents, solvents, and protecting groups consumed during solid- or liquid-phase peptide chain assembly and cleavage
• Resins

• Wang Resin
• Rink Amide Resin
• Merrifield Resin
• Protected Amino Acids

• Fmoc Amino Acids
• Boc Amino Acids

• Coupling Reagents & Activators
• Solvents
• Cleavage & Deprotection Reagents
• Services – Outsourced contract research and manufacturing support covering custom peptide design, synthesis, scale-up, and analytical testing for client organizations

• Custom Peptide Synthesis Services
• Contract Manufacturing (CDMO) Services
• Purification Services
• Analytical & Testing Services

Reagents & Consumables lead the Product Type axis in 2025, ahead of Services and Equipment. Amino acids, resins, coupling reagents and cleavage agents are drawn down with every synthesis cycle, so spend scales with production volume rather than the capital cycle governing synthesizer or purification-system purchases. Once a laboratory or CDMO standardizes on a resin chemistry and amino-acid protection scheme, switching costs lock in repeat reagent orders alongside the installed equipment base. Services is the fastest-growing product type. Sponsors without in-house solid-phase capacity for long or difficult sequences are shifting custom synthesis, scale-up and analytical testing to CDMOs, and the Biosecure Act is pushing that work toward CDMOs outside mainland China as US sponsors reassess supply exposure. Analytical and testing services generate electronic batch records subject to FDA 21 CFR Part 11, a data-integrity requirement that favors CDMOs with validated systems over in-house build-out.

Application

• Therapeutics (largest) – Peptides manufactured to treat or manage disease directly, such as insulin, GLP-1 receptor agonists, and other peptide-based drugs administered to patients

• Oncology
• Metabolic Disorders
• Cardiovascular Diseases
• Infectious Diseases
• Autoimmune & Inflammatory Diseases
• Diagnosis – Peptides synthesized for use in diagnostic assays and test kits, such as antigens or biomarkers that detect diseases or monitor biological conditions
• In Vitro Diagnostics

• Immunoassays
• Radioimmunoassays
• In Vivo Diagnostics
• Diagnostic Imaging Agents

Therapeutics leads the Application axis in 2025, covering peptide drugs across oncology, metabolic, cardiovascular, infectious-disease and autoimmune indications, ahead of the smaller Diagnosis segment. GLP-1 receptor agonists and insulin analogs anchor large-volume manufacturing tied to FDA BLA and NDA approvals and, for EU entry, the EMA centralised procedure; supporting clinical trials run under ICH GCP. Coverage still gates volume, since CMS reimbursement coding under CPT and HCPCS, alongside HTA review in ex-US markets, determines how much manufacturing demand converts into prescribed volume. Diagnosis, though smaller, is gaining ground as peptide antigens and biomarkers move into immunoassay and companion-diagnostic panels tied to the same targeted therapies, sold in the EU under EU MDR and IVDR conformity requirements. CDC surveillance of infectious-disease prevalence is one driver of that biomarker-panel demand.

Regional Analysis

North America

North America accounted for 48.59% of the peptide synthesis market in 2025, the largest of the three regions covered here. The FDA’s 2024 prohibition on BPC-157 in compounding pharmacies tightened scrutiny of unapproved peptide compounds moving through the supply chain, drawing a firmer line between compounded product and candidates advanced through the agency’s BLA and NDA review pathways. Sponsors responded by routing synthesis volume toward validated, GMP-grade capacity built on 21 CFR Part 11-compliant batch records, rather than compounding outlets flagged under the ban. CMS reimbursement codes under the CPT and HCPCS schedules now cover a widening range of GLP-1 indications, and that coverage growth feeds back into reagent and CDMO demand from the region’s GLP-1 and insulin-analog manufacturing programs run by US-headquartered sponsors. That combination keeps reagent and CDMO demand concentrated in the region through 2035.

Europe

Europe held 21.44% of the market in 2025, built on a concentration of specialist contract manufacturers headquartered in Switzerland and Germany, including Bachem, Lonza, PolyPeptide and CordenPharma. Peptide APIs synthesized at these sites feed drug dossiers filed through the EMA’s centralised procedure, and the trial data underpinning those filings must meet ICH GCP conduct standards before national HTA bodies rule on reimbursement. A 2025 European Medicines Agency concept paper to revise Part IV of the EU GMP guideline for advanced therapy medicinal products extends qualification requirements to closed and automated manufacturing platforms, aligning them with the revised Annex 1 sterility standard already in force since August 2023. The revision bears on how these CDMOs qualify isolators, restricted-access barrier systems and single-use equipment as they scale solid-phase and purification lines, and it lands alongside a separate EU MDR compliance burden for the auto-injector pens that deliver GLP-1 and insulin-analog peptides to patients.

Asia Pacific

Asia Pacific took 20.16% share in 2025, anchored by China-headquartered reagent and CDMO capacity at WuXi AppTec and GenScript Biotech, both of which supply amino acids, custom synthesis and analytical testing to sponsors worldwide, and both named among the Chinese biotech suppliers targeted by the pending Biosecure Act restrictions on US federal contracting. Lower-cost solid-phase manufacturing scale in the region continues to draw outsourced synthesis volume away from higher-cost Western capacity for standard, well-characterized sequences, while India’s generic-drug manufacturing base, regulated domestically by the CDSCO, adds further reagent and intermediate supply depth. Regional capacity additions are increasingly built around Fmoc-chemistry lines suited to the shorter, high-volume peptide sequences that dominate generic and biosimilar pipelines.

Competitive Landscape

The peptide synthesis market is moderately consolidated, split between specialist contract manufacturers, reagent and equipment suppliers, and large pharmaceutical sponsors that also manufacture peptide APIs in-house. Competition centers on manufacturing scale and quality record: sponsors selecting a synthesis partner weigh GMP compliance history, batch consistency at scale, and analytical characterization capability alongside price. On the reagent and equipment side, an installed base of synthesizers, purification systems and lyophilizers creates a consumable lock-in effect, since a qualified resin chemistry and amino-acid protection scheme is costly to swap out of a validated production process.

A group of established players leads the market: Bachem Holding AG, CordenPharma International, Lonza Group AG, WuXi AppTec Co., Ltd., PolyPeptide Group AG, Merck KGaA, Novo Nordisk A/S, Eli Lilly and Company, Thermo Fisher Scientific Inc., and GenScript Biotech Corporation. Bachem, Lonza, PolyPeptide and CordenPharma compete primarily as contract manufacturers and CDMOs; Merck KGaA, Thermo Fisher and GenScript as reagent, instrument and custom-synthesis suppliers; and Novo Nordisk and Eli Lilly as sponsors that have built captive peptide-manufacturing capacity around their own GLP-1 portfolios.

Strategic Outlook

The clearest whitespace lies in CDMO-delivered peptide therapeutics for oncology and metabolic indications, where sponsors lacking in-house solid-phase capacity for long or difficult sequences increasingly outsource scale-up work. Contract manufacturers based in Switzerland and Germany, together with China-based reagent suppliers, stand to capture this volume, provided GMP-grade capacity keeps pace with GLP-1-driven demand for large-scale synthesis runs.

By 2035, reagents and consumables are expected to retain primacy while services gain share as outsourcing deepens. Hybrid solid- and liquid-phase synthesis routes are likely to displace slower, manual production steps across both contract and in-house manufacturing, tightening the link between reagent choice and throughput.

Peptide Synthesis Market Report Scope